[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Athens\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":330},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,48,75,103,130,166,189,218,242,263,285,307],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100353194","the-cardiovascular-effect-of-glp-1-agonist-sglt2-inhibitor-and-their-combination-100353194",false,"NCT03878706","The Cardiovascular Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination","The Effect of GLP-1 Agonist, SGLT2 Inhibitor and Their Combination on Endothelial Function, Arterial Stiffness and Left Ventricular Deformation in Patients With Type 2 Diabetes With High Cardiovascular Risk","Inclusion Criteria:\n\n* Subject has type 2 diabetes mellitus\n* Subject has high or very high cardiovascular risk\n* Subject has heart failure with preserved ejection fraction\n\nExclusion Criteria:\n\n* Subject has type 1 diabetes mellitus\n* Subject has kidney disease\n* Subject has retinopathy","ALL","45 Years","80 Years",{"count":20,"type":21},240,"ESTIMATED","12 Months","OBSERVATIONAL","A. Four groups of patients with type 2 diabetes mellitus with high or very high cardiovascular risk or heart failure with preserved ejection fraction (HFpEF) will be studied before and at 6 and 12 months of treatment:\n\n* 60 patients treated with a combination of GLP1 analogue and SGLT2 inhibitor ± metformin\n* 60 patients treated with GLP-1 agonist as a second step after metformin\n* 60 patients treated with SGLT2 inhibitor as a second step after metformin\n* 60 patients treated with a combination of insulin and other antidiabetic agents (metformin - DPP4 inhibitors) Individuals will be equal distributed as far as age, gender and body mass index concerned. In addition, patients suffered from kidney disease and retinopathy are excluded.",[26],"Diabetes Mellitus, Type 2",[28,29,30,31,32,33,34],"Endothelial glycocalyx integrity","Oxidative stress biomarkers","Arterial stiffness","GLS","NT-proBNP","GDF-15","MOTS-c","RECRUITING","2026-03-11",{"date":38,"type":39},"2026-03-13","ACTUAL",{"date":41,"type":39},"2017-11-03",{"date":43,"type":21},"2027-06-30",{"name":45,"class":46},"University of Athens","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":18,"enrollmentInfo":57,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":47},"100629076","the-effect-of-sodium-glucose-co-trnasportert-type-2-inhibitors-on-arterial-stiffness-endothelial-glycocalyx-thickness-and-cardiac-deformation-after-acute-myocardial-infarction-100629076","NCT07469943","The Effect of Sodium Glucose Co-trnasportert Type 2 Inhibitors on Arterial Stiffness, Endothelial Glycocalyx Thickness and Cardiac Deformation After Acute Myocardial Infarction","The Effect of Sodium Glucose Co-trnasportert Type 2 Inhibitors on Arterial Stiffness, Endothelial Glycocalyx Thickness , Left Atrial and Left Ventricular Deformation After Acute Myocardial Infarction","SGLT2i-MI-glyc","Inclusion Criteria:\n\n* STEMI participants with type 2 diabetes or LVEF\\\u003C40%\n\nExclusion Criteria:\n\n1. Chronic kidney disease with estimated glomerular filtration rate (eGFR) \\\u003C60 ml\u002Fmin\u002F1.73 m²\n2. Active malignancy\n3. Autoimmune or autoinflammatory disorders\n4. Severe hepatic impairment\n5. Pregnancy or breastfeeding","18 Years",{"count":58,"type":21},80,"Acute myocardial infarction (MI) remains one of the leading causes of cardiovascular morbidity and mortality worldwide. It most commonly occurs due to acute coronary artery occlusion following rupture or erosion of an atherosclerotic plaque and subsequent thrombus formation. Despite significant advances in reperfusion strategies and guideline-directed pharmacological therapy, patients who survive MI remain at increased risk for adverse cardiovascular outcomes, including heart failure, recurrent myocardial infarction, stroke, and cardiovascular death. Therefore, additional therapeutic strategies that may improve vascular function, myocardial remodeling, and overall cardiovascular prognosis following MI are of considerable clinical interest.\n\nSodium-glucose cotransporter-2 (SGLT2) inhibitors have recently emerged as an important pharmacological class with significant cardiometabolic benefits. Large randomized clinical trials have demonstrated that SGLT2 inhibitors reduce the risk of hospitalization for heart failure and cardiovascular mortality in patients with type 2 diabetes mellitus and in patients with heart failure irrespective of diabetic status. The cardioprotective effects of these agents appear to extend beyond glycemic control and include improvements in myocardial energetics, vascular function, inflammation, and oxidative stress. Emerging evidence suggests that SGLT2 inhibitors may also exert beneficial effects on vascular stiffness, endothelial function, and myocardial remodeling. However, data regarding their potential impact on arterial stiffness, endothelial glycocalyx integrity, and myocardial deformation parameters in the early post-myocardial infarction setting remain limited.\n\nThe primary aim of the present study is to investigate the effect of empagliflozin administration (10 mg daily) on arterial stiffness, endothelial glycocalyx thickness, and myocardial deformation indices of the left ventricle and left atrium during a 12-month follow-up period in patients presenting with ST-segment elevation myocardial infarction (STEMI).\n\nSecondary objectives include:\n\n1. evaluation of the incidence of major adverse cardiovascular events (MACE), defined as cardiovascular death, recurrent myocardial infarction, and acute ischemic stroke;\n2. investigation of the association between the occurrence of MACE and vascular and myocardial functional parameters, including indices of arterial stiffness, endothelial glycocalyx integrity, and myocardial strain measurements; and\n3. assessment of oxidative stress burden through circulating biomarkers. This prospective observational study will include adult patients diagnosed with acute STEMI who are hospitalized in the Second University Cardiology Clinic of \"Attikon\" General Hospital. All participants will provide written informed consent prior to enrollment and will receive standard guideline-directed therapy for acute myocardial infarction according to the current European Society of Cardiology (ESC) guidelines.\n\nParticipants will be allocated into two groups. Group A will include patients receiving empagliflozin 10 mg once daily, initiated either at hospital discharge in patients with concomitant type 2 diabetes mellitus or in patients without diabetes who present with reduced left ventricular ejection fraction (LVEF \\\u003C40%). Group B will serve as the control group and will not receive empagliflozin therapy. The anticipated sample size of the study is 80 patients, with approximately 40 participants in each group.\n\nExclusion criteria include chronic kidney disease with estimated glomerular filtration rate (eGFR) \\\u003C60 ml\u002Fmin\u002F1.73 m², active malignancy, autoimmune or autoinflammatory disorders, severe hepatic impairment, and pregnancy or breastfeeding.\n\nParticipants will undergo detailed evaluation at baseline and at 3, 6, and 12 months. Arterial stiffness will be assessed through measurement of carotid-femoral pulse wave velocity (cf-PWV) using the Complior SP system, which represents the gold standard non-invasive method for evaluating large-artery stiffness. In addition, 24-hour pulse wave analysis will be performed using the Mobil-O-Graph device to obtain central hemodynamic parameters.\n\nEndothelial function will be evaluated through assessment of endothelial glycocalyx thickness in sublingual microvessels using Sidestream Dark Field (SDF) imaging with the GlycoCheck system. Glycocalyx integrity will be quantified by the Perfused Boundary Region (PBR) index, which reflects erythrocyte penetration into the glycocalyx layer and serves as a marker of endothelial barrier dysfunction.\n\nCardiac structure and function will be assessed using two-dimensional speckle-tracking echocardiography. Global longitudinal strain (GLS) of the left ventricle will be calculated using the standard 17-segment model from apical views, while left atrial strain will be measured to evaluate atrial reservoir and contractile function, providing sensitive markers of myocardial remodeling after infarction",[61,62],"Myocardial Infarction (MI)","Diabete Type 2",[64,65,66,67],"arterial stiffness","sglt2i","myocardial deformation","endothelial glycocalyx","2026-03-10",{"date":38,"type":39},{"date":71,"type":39},"2026-01-09",{"date":73,"type":21},"2028-12-20",{"name":45,"class":46},{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":16,"minAge":56,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":87,"conditions":88,"keywords":92,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":96,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":102},"100617921","the-effect-of-lipoprotein-a-on-arterial-stiffness-endothelial-function-and-myocardial-deformation-100617921","NCT07324902","The Effect of Lipoprotein (a) on Arterial Stiffness, Endothelial Function and Myocardial Deformation","The Effect of Lipoprotein (a) on Arterial Stiffness, Endothelial Function and Left Atrial and Left Ventricular Deformation - An Observational Study.","Lpa_endo","Inclusion Criteria:\n\n* Adults participants 18-75 years old\n* Willing to sign the informed consent and paerticipate in the study\n\nExclusion Criteria:\n\n* History of autoimmune\u002Fautoinflammatory disease,\n* Severe valvular heart disease,\n* severe chronic kidney disease(eGFR\\\u003C60 ml\u002Fmin\u002F1.73 m2),\n* Active Pregnancy\n* Severe hepatic impairment.",true,"75 Years",{"count":86,"type":21},300,"1. Introduction Lipoprotein(a), or Lp(a), is a type of lipoprotein that is structurally similar to LDL (low-density lipoprotein) but carries an additional protein called apolipoprotein (a).\n2. Purpose of the Study\n\n   The primary purpose of this study is to investigate the effect of Lp(a) levels on arterial stiffness, endothelial function, and left atrial (LA) and left ventricular (LV) deformation over a 12-month follow-up period.\n\n   Secondarily, the study will investigate:\n   * a) The incidence of major adverse cardiovascular events (MACE), including cardiovascular death, acute myocardial infarction, and acute stroke.\n   * b) The correlation between MACE incidence and parameters of arterial stiffness, endothelial function, and LA\u002FLV deformation.\n   * c) The levels of oxidative load markers.\n3. Materials and Methods This observational study will include adults aged 18-75 years (regardless of gender) who visit the outpatient clinics of the 2nd University Cardiology Clinic at \"Attikon\" General Hospital. All participants will sign a consent form. A full medical history, clinical examination, and blood collection will be performed to determine levels of Total Cholesterol, LDL-C, HDL-C, triglycerides, and Lp(a) at each visit..\n\nParticipants will be divided into three groups:\n\n* Group A: Lp(a) ≥50 mg\u002FdL with Total Cholesterol\\\u003C200 mg\u002Fdl\n* Group B : Lp(a) \\\u003C50 mg\u002FdL. with Total Cholesterol\\>200 mg\u002Fdl\n* Group C (Control): Lp(a) \\\u003C50 mg\u002FdL. with Total Cholesterol\\\u003C200 mg\u002Fdl At each group n ≥ 100 participants are anticipated.\n\nMeasurements at baseline, at 6 and at 12 months:\n\n* Arterial Stiffness: Determination of carotid-femoral pulse wave velocity (cf-PWV) using the Complior SP device and 24-hour pulse wave analysis with the Mobil-O-Graph device.\n* Endothelial Function: Measurement of the endothelial glycocalyx thickness of sublingual capillaries using a Sidestream Dark Field (SDF) camera (GlycoCheck). This is expressed through the perfused boundary region (PBR) index.\n* Cardiac Deformation: Use of two-dimensional strain (speckle tracking) to calculate the Global Longitudinal Strain (GLS) of the LV and LA strain.\n* Oxidative Load: Determination of malondialdehyde (MDA) and protein carbonyls (PCs) levels as markers of oxidative stress using spectrophotometric kits.\n\nStatistical Analysis: Comparisons regarding the changes in these markers over 6 and 12 months will be conducted between the three groups.",[89,90,91],"Lipoprotein Disorder","Arterial Stiffness","Endothelial Dysfunction",[93,94,67,66,95],"lipoprotein a","artrial stiffness","oxidative stress",{"date":36,"type":39},{"date":98,"type":39},"2024-09-25",{"date":100,"type":21},"2027-08-17",{"name":45,"class":46},2,{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":47},"100598247","burnout-syndrome-in-the-intensive-care-unit-before-and-during-a-palliative-care-trial-100598247","NCT07069010","Burnout Syndrome in the Intensive Care Unit Before and During a Palliative Care Trial","Evaluation of Burnout Syndrome Among Healthcare Professionals in Intensive Care Units Within the EPIC (Enhancing Palliative Care in ICU) Research","BURNOUT-EPIC","Inclusion Criteria:\n\n* ICU clinicians (nurses, physicians, advanced practice providers) actively caring for critically ill patients\n* Employed in participating ICUs for ≥3 months prior to study start\n* Willing to complete both pre- and during-intervention surveys\n* Consent to participate in educational tele-palliative care trial\n\nExclusion Criteria:\n\n* Locum tenens or temporary staff not continuously assigned to the unit\n* Clinicians on leave (medical, parental, or extended leave) during either survey period\n* Prior enrollment in similar palliative care training within past 6 months",{"count":112,"type":21},100,"One hundred ICU doctors, nurses and psychologists from the 28 units participating in the EPIC stepped-wedge trial (ClinicalTrials.gov NCT06605079) will each complete the same four-part survey twice-once during their unit's usual-care phase and again during the EPIC tele-palliative-care intervention. The questionnaire begins with Part A, gathering demographic and professional details such as age, gender, family status, education, role, years of ICU service, shift patterns, leave days and any prior palliative-care or ethics training. Part B then probes 22 workplace stressors and ethical dilemmas-resource constraints, family pressures, moral conflicts, emotional distancing from colleagues, perceived control over decisions and work-life balance-using a five-point frequency scale. Part C merges a 19-item Maslach Burnout Inventory subset (emotional exhaustion, depersonalization, personal accomplishment) on a seven-point frequency scale with a 16-item Oldenburg Burnout Inventory subset (exhaustion, disengagement) on a four-point agreement scale. Finally, Part D employs Neff's 16-item Self-Compassion Scale-rated from almost never to almost always-to assess self-kindness, common humanity, mindfulness, self-judgment, isolation and over-identification. Within-subject, repeated-measures analyses of total and subscale scores will quantify how EPIC's blended-learning curriculum and standardized teleconsultations shift clinician burnout profiles and self-compassion over time.",[115],"Burnout Syndrome",[117,118,119,120,121],"ICU burnout","Moral distress","self compassion","Tele-palliative care","repeated measures survey","2025-07-29",{"date":124,"type":39},"2025-08-01",{"date":126,"type":39},"2025-07-15",{"date":128,"type":21},"2027-09-30",{"name":45,"class":46},{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":136,"eligibilityCriteria":137,"healthyVolunteers":83,"sex":16,"minAge":56,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":139,"conditions":140,"keywords":149,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":165},"100589079","flecainide-in-idiopathic-premature-ventricular-contractions-and-related-cardiomyopathy-100589079","NCT06949748","Flecainide in Idiopathic Premature Ventricular Contractions and Related Cardiomyopathy","UNIFLECA Study: Prospective Cohort Study on Flecainide's Impact on Persistent High Premature Ventricular Contraction Burden and PVC-Induced Cardiomyopathy","UNIFLECA","Inclusion Criteria:\n\n* Frequent idiopathic PVCs (burden \\>5% on multiple 24-hour Holter ECG recordings)\n* Normal cardiac structure and function on echocardiography\n* No late gadolinium enhancement or myocardial scar on cardiac MRI\n* Normal coronary angiography (excluding ischemic cardiomyopathy)\n* Normal serum electrolytes and renal function\n* Willingness to comply with follow-up schedule and drug titration\n\nExclusion Criteria:\n\n* Structural heart disease\n* Ischemic heart disease (confirmed by angiography)\n* History of sustained ventricular arrhythmias\n* Left ventricular ejection fraction (LVEF) \\\u003C40% at baseline\n* Brugada syndrome, long QT syndrome, or other channelopathies\n* Contraindications to class IC agents\n* Use of concurrent antiarrhythmics or proarrhythmic drugs",{"count":86,"type":21},"The UNIFLECA study is a prospective, single-arm, observational cohort evaluating the efficacy, safety, and tolerability of flecainide (in the form of Sanocard) in adults with frequent idiopathic premature ventricular contractions (PVCs) and suspected PVC-induced cardiomyopathy (PVCi-CMP). Frequent PVCs-defined as a burden \\>5% on two separate 24-hour Holter recordings-are increasingly recognized as a cause of reversible systolic dysfunction in patients without structural heart disease.\n\nParticipants undergo a comprehensive baseline evaluation including echocardiography, occasionally cardiac MRI, and coronary angiography or equivalent testing to confirm the absence of structural abnormalities. Patients are enrolled only if they are ineligible or unwilling to undergo catheter ablation, and have no contraindications to flecainide.\n\nFlecainide therapy is initiated at a starting dose of 100 mg\u002Fday and titrated up to 200 mg\u002Fday, guided by ECG findings, symptom response, and QRS duration. Regular follow-up occurs at three-month intervals over three years, with periodic 24-hour Holter monitoring and assessment of symptoms, LVEF, and adverse events.\n\nThe primary outcome is the reduction in PVC burden. Secondary outcomes include improvement in LVEF, symptom relief (measured by structured questionnaires), adverse effects, and long-term treatment adherence. The study aims to generate real-world data on the non-invasive management of PVCs with flecainide and explore its role as an alternative to ablation in carefully selected patients.",[141,142,143,144,145,146,147,148],"Premature Ventricular Beats","Premature Ventricular Complexes","Premature Ventricular Contraction (PVC)","Arrhythmia Ventricular","Ventricular Dysfunction, Left","Ventricular Dysfunction","Cardiomyopathies, Secondary","Cardiomyopathies",[150,151,136,152,153,154,155,156],"Flecainide","Sanocard","PVC induced CMP","PVC","Premature Ventricular Contraction","Outflow Tract PVC","NonOutflow Tract PVC","2025-06-27",{"date":159,"type":39},"2025-07-02",{"date":161,"type":39},"2024-04-26",{"date":163,"type":21},"2027-12-01",{"name":45,"class":46},6,{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":172,"eligibilityCriteria":173,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":84,"enrollmentInfo":174,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":176,"conditions":177,"keywords":179,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":181,"lastUpdatePostDateStruct":182,"startDateStruct":184,"completionDateStruct":186,"leadSponsor":188,"locationsCount":47},"100584179","the-effect-of-cytisine-treatment-for-smoking-cessation-on-cardiovascular-function-in-adult-smokers-100584179","NCT06885970","The Effect of Cytisine Treatment for Smoking Cessation on Cardiovascular Function in Adult Smokers","The Effect of Cytisine Treatment for Smoking Cessation on Cardiovascular Function in Adult Smokers of Conventional Combustible Cigarettes and New Tobacco Products-Observational Study.","Cytisin-angio","Inclusion Criteria:\n\n* Smokers willing to participate\n\nExclusion Criteria:\n\n* history of coronary artery disease, active malignancy, history of severe liver and renal failure, history of autoimmune disease.",{"count":175,"type":21},200,"Introduction: Pharmacological interventions can enhance smoking cessation success and long-term abstinence. Cytisine, a plant derived alkaloid, is a selective partial agonist at alpha-4 beta-2 nicotinic acetylcholine receptors, which are crucial in nicotine dependence.\n\nAim of the Study The primary objective of this observational study is to evaluate the efficacy of cytisine in a standard 25-day dosing regimen among adult smokers and users of alternative nicotine products (e-cigarettes or heated tobacco). The study will assess the impact of cytisine on cardiovascular function, including arterial stiffness, cardiac deformation, and endothelial glycocalyx integrity.\n\nThe secondary aim is to determine relapse rates post-treatment, treatment side effects, and new cardiovascular events during the treatment period and at six-month follow-up.\n\nMaterials and Methods: This observational study will recruit smokers visiting the smoking cessation unit at the 2nd Department of Cardiology, Attikon University Hospital, Athens. All participants will receive counseling and treatment from the attending physician.\n\nA minimum of 200 participants will be enrolled, categorized into:\n\n• At least 50 receiving cytisine in the standard dosing regimen: Days 1-3: 1 tablet every 2 hours (6 tablets daily) Days 4-12: 1 tablet every 2.5 hours (5 tablets daily) Days 13-16: 1 tablet every 3 hours (4 tablets daily) Days 17-20: 1 tablet every 5 hours (3 tablets daily) Days 21-25: 1-2 tablets daily\n\n* At least 50 receiving nicotine replacement therapy\n* At least 50 receiving prolonged cytisine therapy (3 mg, three times daily for 12 weeks)\n* At least 50 who do not intend to quit smoking (control group)\n\nAssessments will be conducted at baseline, one month, and six months post-recruitment. The following measurements will be performed:\n\nA. Arterial Stiffness: Pulse wave velocity (cf-PWV) using the Complior device to measure arterial stiffness, Augmentation index and pulse wave velocity using the Arteriograph device via brachial artery cuff.\n\nB. Endothelial Glycocalyx Integrity: Perfused boundary region (PBR) assessment of sublingual microvasculature using a Sidestream Dark Field (SDF) camera.\n\nC. Cardiac Function: Left ventricular ejection fraction (LVEF), myocardial strain (GLS), and myocardial work assessment via speckle-tracking echocardiography (Echopac 203, GE Horten Norway).The investigators will also calculate myocardial work (MW) using pressure-strain loop analysis.\n\nD. Oxidative Stress: Plasma malondialdehyde (MDA) and protein carbonyl (PC) levels measured via spectrophotometry.\n\nE. Smoking Cessation Monitoring: Exhaled carbon monoxide (CO) measured using a commercial device (Smokelyzer, Bedfont Scientific Ltd.).\n\nThis study aims to provide valuable insights into cytisine's effectiveness in smoking cessation and its impact on cardiovascular health.",[178,90,91],"Smoking Cessation",[64,180,66,67],"smoking cessation","2025-03-27",{"date":183,"type":39},"2025-04-02",{"date":185,"type":39},"2024-11-12",{"date":187,"type":21},"2025-08-10",{"name":45,"class":46},{"id":190,"slug":191,"hasResults":11,"nctId":192,"briefTitle":193,"officialTitle":194,"acronym":4,"eligibilityCriteria":195,"healthyVolunteers":83,"sex":16,"minAge":196,"maxAge":56,"enrollmentInfo":197,"targetDuration":4,"studyType":199,"phases":200,"briefSummary":202,"conditions":203,"keywords":206,"overallStatus":209,"whyStopped":4,"lastUpdateSubmitDate":210,"lastUpdatePostDateStruct":211,"startDateStruct":213,"completionDateStruct":215,"leadSponsor":217,"locationsCount":47},"100574962","chios-mastic-toothpaste-and-halitosis-and-oral-hygiene-in-orthodontic-patients-100574962","NCT06766097","Chios Mastic Toothpaste and Halitosis and Oral Hygiene in Orthodontic Patients","The Effect of Chios' Mastic Toothpaste on Halitosis and Oral Hygiene in Orthodontic Patients: a Randomized Clinical Trial","Inclusion Criteria:\n\nPatients eligible for the trial must comply with all of the following at randomization:\n\n• Age between 13 and 18 years for the group with conventional orthodontic appliances.\n\nThis age group represents the majority of patients seeking orthodontic treatment and is homogeneous regarding occupational status (high-school and lyceum students in Greece). Younger patients might present with cooperation problems.\n\n* Good general health.\n* Orthodontic fixed labial appliances on the maxillary and mandibular arch, brackets at least on 20 teeth for more than 4 months before enrollment and estimated duration of the treatment more than 1 month, bands on the first molars, extraction cases patients could be enrolled at least two months after the last extraction.\n* Total initial VSCs levels above the baseline level of 150ppb.\n\nExclusion Criteria:\n\nPatients will be excluded for any of the following reasons:\n\n* Active caries\n* Periodontitis\n* Dental fluorosis \u002F dysplasia of the teeth\n* Syndromes, mental disabilities and craniofacial deformities\n* Smoking or use of other tobacco products\n* Allergy to mastic\n* Antibiotics during the last 2 months\n* Chlorhexidine in the previous 3 weeks\n* Participation in other trials","13 Years",{"count":198,"type":21},30,"INTERVENTIONAL",[201],"NA","The aim of this trial was to investigate the effect of mastic toothpaste on halitosis using as proxy the levels of the Volatile Sulfur Compounds (VSCs), and the effect on plaque and gingival indices in adolescents undergoing orthodontic treatment with fixed conventional labial appliances.",[204,205],"Halitosis","Orthodontic Appliance Complication",[204,207,208],"Mastic","Orthodontic appliance","NOT_YET_RECRUITING","2025-01-03",{"date":212,"type":39},"2025-01-09",{"date":214,"type":21},"2025-01-07",{"date":216,"type":21},"2025-02-28",{"name":45,"class":46},{"id":219,"slug":220,"hasResults":11,"nctId":221,"briefTitle":222,"officialTitle":223,"acronym":4,"eligibilityCriteria":224,"healthyVolunteers":83,"sex":16,"minAge":56,"maxAge":225,"enrollmentInfo":226,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":228,"conditions":229,"keywords":230,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":47},"100412107","the-role-of-glycocalyx-integrity-in-the-primary-prevention-of-major-cardiovascular-events-100412107","NCT04646252","The Role of Glycocalyx Integrity in the Primary Prevention of Major Cardiovascular Events","Impaired Endothelial Glycocalyx Predicts Adverse Outcome in Subjects Without Overt Cardiovascular Disease: a 6 Year Follow up Study","Inclusion Criteria:\n\nWe recruit individuals who were referred for a routine screening in the primary prevention outpatient clinic of Attikon University hospital.\n\nExclusion Criteria:\n\n* History of Coronary artery disease,\n* History of Peripheral Arterial Disease,\n* History of Heart failure\n* History of Stroke\n* hepatic failure\n* renal failure,\n* active neoplasia\n* poorly controlled DM, defined as Hba1C\\>7%","85 Years",{"count":227,"type":21},500,"The researchers intend to recruit individuals who are referred for a routine screening in the primary prevention outpatient clinic of Attikon University hospital, Athens According to institutional protocols, a detailed medical history for atherosclerotic risk factors and current medication is recorded and a baseline clinical examination is performed. Moreover fasting blood samples are drawn to diagnose the presence of diabetes mellitus and hyperlipidemia. Glycocalyx examination is performed at the same visit. The subjects are revaluated at one month and then followed up according to the attending physician's instructions. Pulse wave velocity and the rest pulse wave analysis parameters were also calculated to determine the additive predictive value for cardiovascular events beyond SCORE2. All subjects are followed up for adverse events (death, stroke, myocardial infarction, hospitalization for heart failure) for 6 years after enrollment via telephonic contact and planned appointment at the outpatient clinic.",[91,90],[231,232,233],"perfused boundary region","primary prevention of major cardiovascular events","integrity of endothelial glycocalyx","2024-05-28",{"date":236,"type":39},"2024-05-29",{"date":238,"type":39},"2013-01-10",{"date":240,"type":21},"2027-05-28",{"name":45,"class":46},{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":247,"acronym":4,"eligibilityCriteria":248,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":249,"enrollmentInfo":250,"targetDuration":4,"studyType":199,"phases":251,"briefSummary":252,"conditions":253,"keywords":255,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":257,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":47},"100402427","effect-of-olivomed-olive-extract-on-endothelial-cardiac-and-vascular-function-100402427","NCT04520126","Effect of Olivomed (Olive Extract) on Endothelial, Cardiac and Vascular Function","Effect of Olivomed (Olive Extract) on Endothelial, Cardiac and Vascular Function of Patients With Stable Coronary Artery Disease","Inclusion Criteria:\n\n1. Age \\\u003C70 years\n2. Stable coronary heart disease\n3. Patients with acute coronary syndrome who have undergone percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG), 2 months must have passed since the incident\n4. High LDL levels, low HDL, high triglycerides\n\nExclusion Criteria:\n\n1. Age\\> 70 years\n2. Patient with diabetes\n3. Patient with hypertension\n4. Patient with liver disease\n5. Patient with thyroid disease\n6. Patient with active malignancy\n7. Patient with a disease that affects inflammatory markers (rheumatic diseases, etc.)\n8. Patient with chronic renal failure (creatinine\\> 2 mg \u002F dl)\n9. Patient treated chronically with corticosteroids\n10. Patient who has joined a weight loss program or any dietary intervention or intensive exercise programme within the previous 2 months or consumes multivitamin preparations with antioxidant properties.","70 Years",{"count":198,"type":21},[201],"Olive extracts are considered to have antioxidant properties. The investigators will study the effect of olive extracts containing hydroxytyrosol (HT)-olivomed and combination of Oleuropein (OL), Hydroxytyrosol (HT), Oleocanthal (OC) - olivomedSmart on endothelial, cardiac and vascular function in patients with coronary artery disease .",[254],"Coronary Artery Disease",[256],"olive oil, myocardial deformation, glycocalyx",{"date":236,"type":39},{"date":259,"type":39},"2020-12-01",{"date":261,"type":21},"2026-08-01",{"name":45,"class":46},{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":4,"eligibilityCriteria":269,"healthyVolunteers":11,"sex":16,"minAge":56,"maxAge":249,"enrollmentInfo":270,"targetDuration":271,"studyType":23,"phases":4,"briefSummary":272,"conditions":273,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":280,"completionDateStruct":282,"leadSponsor":284,"locationsCount":102},"100380752","postoperative-relapses-in-ms-patients-100380752","NCT04237675","Postoperative Relapses in MS Patients","Assessment of Risk of Postoperative Relapses in Patients With Multiple Sclerosis; an Observational Study","Inclusion Criteria: diagnosed MS -\n\nExclusion Criteria: refuse to participate\n\n\\-",{"count":86,"type":21},"1 Year","The aim of the study is to record any relapses during one year postoperatively in patients and parturients diagnosed with MS who received general or regional anesthesia",[274,275,276],"Multiple Sclerosis Relapse","Surgery","Anesthesia","2020-01-19",{"date":279,"type":39},"2020-01-23",{"date":281,"type":39},"2019-12-20",{"date":283,"type":21},"2027-12",{"name":45,"class":46},{"id":286,"slug":287,"hasResults":11,"nctId":288,"briefTitle":289,"officialTitle":289,"acronym":290,"eligibilityCriteria":291,"healthyVolunteers":83,"sex":16,"minAge":56,"maxAge":292,"enrollmentInfo":293,"targetDuration":4,"studyType":199,"phases":295,"briefSummary":296,"conditions":297,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":299,"lastUpdatePostDateStruct":300,"startDateStruct":302,"completionDateStruct":304,"leadSponsor":306,"locationsCount":102},"100370068","acute-exposure-to-diesel-prolong-effects-on-inflammation-and-vasculature-100370068","NCT04098536","Acute Exposure to Diesel: Prolong Effects on Inflammation and Vasculature","DEVA","Inclusion Criteria:\n\n* Healthy subjects\n\nExclusion Criteria:\n\n* Chronic diseases Cardiovascular diseases Respiratory diseases Pregnacy","60 Years",{"count":294,"type":21},40,[201],"Cross-over double-blind study. Healthy subjects will be exposed to diesel exhaust fumes and\u002For filtered air during a 2-hour session. Several parameters will be assesed i.e. endothelial function will be assessed with flow mediated dilation (FMD) techniques, arterial stiffness with pulse wave velocity (PWV) and reflected waves with augmentation index (AIx). C reactive protein (CRP), fibrinogen, protein C levels and protein S activity will be also measured. Heart rate variability and standard deviation of normal to normal intervals R-R intervals (SDNN) will be used to assess sympathetic activity. Measurements were assessed before, 2 and 24 hours after diesel exposure.",[298],"Atherosclerosis","2019-09-21",{"date":301,"type":39},"2019-09-24",{"date":303,"type":39},"2015-01-01",{"date":305,"type":21},"2026-12-31",{"name":45,"class":46},{"id":308,"slug":309,"hasResults":11,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":83,"sex":16,"minAge":314,"maxAge":4,"enrollmentInfo":315,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":317,"conditions":318,"keywords":320,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":325,"completionDateStruct":327,"leadSponsor":329,"locationsCount":102},"100315330","environment-and-cardiovascular-disease-the-corinthia-study-100315330","NCT03385122","Environment and Cardiovascular Disease: The Corinthia Study","Environmental Pollution and Health of Corinth Region. Corinthia Study","Inclusion Criteria:\n\n* Inhabitants of Corinthia Region\n\nExclusion Criteria:\n\n* Inability and unwillingness to obtain informed consent\n* Individuals less than 40 years of age","40 Years",{"count":316,"type":21},2500,"Environmental factors constitute an important but underappreciated risk factor towards the development and progression of cardiovascular disease (CVD). Environmental exposure in variable pollutants is implicated in the derangement or propagation of adverse pathophysiological processes linked with atherosclerosis, including genetic, hemodynamic, metabolic, oxidative and inflammation parameters. However no data exists concerning environmental pollution in rural or semi-rural areas. Therefore the purpose of the \"Corinthia\" study is to examine the impact of environmental pollution in indices of cardiovascular morbidity and mortality in a cross-sectional and longitudinal design. Corinthia study began in October 2015 and is planned to recruit 2400 individuals from different regions of Corinthia country with different environmental exposure to pollutants and different patterns of soil-ground and\u002For air pollution until September 2018. Baseline measurements will include lifestyle measurements, anthropometric characteristics and a comprehensive cardiovascular examination. The follow-up is planned to extent, prospectively, up to 10 years and this study is anticipated to provide valuable data on the distinct impact of soil and air pollution in early markers of atherosclerosis and cardiovascular disease and in the overall impact of environment pollution to cardiovascular morbidity and mortality.",[319],"Cardiovascular Diseases",[321],"Cardiovascular disease","2017-12-26",{"date":324,"type":39},"2017-12-28",{"date":326,"type":39},"2015-10-20",{"date":328,"type":21},"2030-12-31",{"name":45,"class":46},""]